홈 > 시장보고서 > 의약품

시장보고서

상품코드

1297810

세계의 화농성한선염 시장(2023-2030년)

Global Hidradenitis Suppurativa Market - 2023-2030

발행일: 2023년 06월 | 리서치사:

DataM Intelligence | 페이지 정보: 영문 200 Pages | 배송안내 : 1-2일 (영업일 기준)

■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

시장 개요

세계 화농성한선염 시장은 2022년 7억 2,560만 달러에 달할 것으로 예상되며, 2030년에는 11억 달러로 성장할 것으로 예측됩니다. 세계 화농성한선염 시장은 2023년부터 2030년까지 예측 기간 동안 4.8%의 CAGR을 보일 것으로 예상됩니다.

피부과 의사나 피부과 의사는 화농성한선염 환자를 진단하고 치료하는 의료 전문가 중 한 명입니다. 그들은 증상의 심각성을 판단하고 적절한 치료법(항생제, 항염증제, 면역억제제 등)을 추천하고 상처 치료 및 통증 관리 방법을 지도합니다.

시장 역학

적극적인 주요 업체들이 예측 기간 동안 세계 화농성한선염 시장의 성장을 촉진

활동적인 주요 플레이어와 정부의 승인이 시장을 주도하고 있습니다. 예를 들어, 2023년 6월 유럽위원회(EC)는 노바티스의 코센틱스(secukinumab)를 표준 전신 화농성한선염 치료제로 충분한 효과를 얻지 못하는 활동성 중등도 및 중증 화농성한선염 환자에게 사용할 수 있도록 승인했습니다.

전 세계적으로 100만 명 이상이 코센틱스로 치료를 받고 있습니다. 노바티스는 코센틱스를 화농성한선염 환자들에게 신속하고 장기적인 증상 완화를 제공하는 치료 옵션으로 인정받고 있습니다.

노발티스는 이미 확립된 환자 지원 및 시장 진입 프로그램을 통해 코센틱스에 대한 신속하고 광범위한 접근을 촉진할 수 있는 유리한 위치에 있습니다. 이번 획기적인 승인은 긴급한 의료 수요에 대응하는 고품질 의약품을 제공한다는 노바티스의 목표에 큰 진전을 이루게 되었다는 것을 의미합니다.

화농성한선염 환자 수의 증가는 예측 기간 동안 화농성한선염 시장의 성장을 촉진

2022년 Clinical Dermatology Review에 게재된 논문에 따르면 화농성한선염은 이전에 생각했던 것보다 더 널리 퍼져 있으며, 추정 인구 유병률은 1-4%입니다. 화농성한선염의 발생을 정확하게 추정하는 것은 오진 및 정확한 인구 통계의 부족으로 인해 더욱 복잡해졌습니다.

화농성한선염은 사춘기 이후 자주 발생하며, 대부분 20-30대에 증상이 나타납니다. 환자 분포는 여성이 더 많습니다. 생물학적 제제인 아달리무맙(ADA)이 1차 선택 약물로 널리 채택되면서 다양한 생물학적 제제의 화농성한선염 치료에 대한 효능이 검토되기 시작했습니다.

산학협력은 세계 화농성한선염 시장 성장 기회를 제공

예를 들어, 2022년 3월, 피부 건강 전문 다국적 바이오제약 기업 알미랄(Almirall, S.A.)은 만성 염증성 피부 질환인 화농성한선염의 유발 원인에 대한 지식을 높이기 위해 미시간 대학교와 협력했습니다.

이번 제휴를 통해 미시간대학교의 요한 E. 구정선 박사의 피부과와 알루미나의 피부질환에 대한 전문지식을 결합하여 만성질환의 해리와 섬유화 등 질환의 본질적인 특징을 연구하게 됩니다.

COVID-19 영향 분석

COVID-19의 유행은 화농성한선염 시장에 큰 영향을 미치고 있습니다. 많은 의료 전문가들이 COVID-19 감염 위험을 줄이기 위해 원격 의료 및 가상 진료 플랫폼을 활용하고 있습니다. 이러한 기술은 환자와 의료진 사이에 다양한 커뮤니케이션 채널을 제공하지만, 특히 신체 검사나 시술이 필요한 경우 HS 관리의 모든 측면에 최선의 선택이 아닐 수도 있습니다.

러시아-우크라이나 분쟁 분석

러시아-우크라이나 분쟁이 화농성한선염 시장에 미치는 영향은 복잡하고 다면적입니다. 분쟁과 폭력 기간 동안에는 의료 서비스 이용이 방해받을 수 있습니다. 병원과 의료시설이 피해를 입거나 접근이 불가능할 수 있으며, 의료 종사자들은 이사를 해야 하거나 긴급한 치료를 받아야 할 수도 있습니다. 이는 영향을 받는 지역에 거주하는 사람들의 건강 진단, 치료 및 관리에 영향을 미칠 수 있습니다.

Market Overview

The Global Hidradenitis Suppurativa Market reached US$ 725.6 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 1.1 billion by 2030. The Global Hidradenitis Suppurativa Market is expected to exhibit a CAGR of 4.8% during the forecast period 2023-2030.

Dermatologists and Dermatologic surgeons are among the healthcare experts who diagnose and treat hidradenitis suppurative patients. They determine the condition's severity, recommend the proper therapies (such as antibiotics, anti-inflammatory medications, and immunosuppressants), and offer instructions on how to treat wounds and manage pain.

Market Dynamics

Active key players are boosting the global hidradenitis suppurativa market growth during the forecast period.

Active key players and approval by the government drive the market. For instance, in June 2023, The European Commission (EC) authorized Cosentyx (secukinumab) by Novartis for use in individuals with active moderate to severe hidradenitis suppurative who have not responded adequately to standard systemic hidradenitis suppurative therapy.

More than 1 million people have received treatment with Cosentyx worldwide. The company offers Cosentyx as a well-respected therapy option, providing hidradenitis suppurative sufferers with quick and long-lasting symptom alleviation.

Novartis is well-positioned to facilitate quick and extensive access to Cosentyx because of its well-established patient assistance and market access programs. This milestone approval represents a significant advancement in our goal of providing high-quality medications that address urgent medical needs.

An increasing number of patients with hidradenitis suppurativa is boosting the Global Hidradenitis Suppurativa Market growth during the forecast period.

As per the article published in Clinical Dermatology Review in 2022, hidradenitis suppurativa is more prevalent than previously believed, with an estimated population prevalence of 1% to 4%. The right estimation of the occurrence of hidradenitis suppurativa is further complicated by misdiagnosis and a lack of precise demographic statistics.

After puberty, hidradenitis suppurativa frequently develops, with most individuals experiencing symptoms in their 20s and 30s. When it comes to case distribution, women predominate. The effectiveness of various biologic drugs in the treatment of hidradenitis suppurativa has started to be investigated due to the widespread adoption of the biologic agent adalimumab (ADA) as a first-line therapeutic agent.

Industry-academia partnership provides Global Hidradenitis Suppurativa Market growth opportunities.

For instance, in March 2022, Almirall, S.A., a multinational biopharmaceutical business specializing in skin health, partnered with the University of Michigan to advance knowledge of the triggers of the chronic, inflammatory skin disorder hidradenitis suppurativa.

Through this collaboration, Dr. Johann E. Gudjonsson's dermatology department at the University of Michigan and Almirall's expertise in skin disorders will be merged to study essential features of this illness, such as chronic disease dissection and fibrosis.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the Hidradenitis Suppurativa market. Numerous healthcare professionals have utilized telemedicine and virtual care platforms to reduce the risk of COVID-19 transmission. Although these technologies offer a different communication channel between patients and medical staff, they might not be the best option for all facets of HS management, particularly when physical examinations and procedures are required.

Russia-Ukraine Conflict Analysis

The impact of the Russia-Ukraine war on the hidradenitis suppurativa market is complex and multifaceted. Access to healthcare may be hampered during periods of unrest and violence. Healthcare workers may be relocated or occupied with emergency treatment, while hospitals and medical facilities may be damaged or inaccessible. This may affect HS diagnosis, treatment, and management for people living in the impacted locations.

Segment Analysis

The Global Hidradenitis Suppurativa Market is segmented based on clinical stage, skin condition, treatment type, route of administration, end-user, distribution channel, and region.

The medications segment is expected to hold a dominant position in the market over the forecast period.

The medications segment had the highest market stake, accounting for approximately 32.5% of the Hidradenitis Suppurativa market in 2022. If tests reveal a bacterial infection and lumps that are extremely painful, inflamed, and leaking pus, then you may be given a 1- or 2-week course of antibiotics. Low doses of antibiotics may be used to stop inflammation if bacterial infection is absent. A longer course of antibiotics will be taken for at least three months to lessen the number of lumps that form.

Antibiotics can be administered orally, topically (as a cream), or as tablets, capsules, or liquids. Lymecycline, doxycycline, erythromycin, and clarithromycin are different antibiotic kinds. Clindamycin and rifampicin together are beneficial in treating severe cases of hidradenitis suppurativa.

Geographical Analysis

Increasing collaborations and partnerships among the key players and advancement in hidradenitis suppurativa dominate the European region.

Europe is expected to dominate secondly the hidradenitis suppurativa market, accounting for around 25.5% of this market. For instance, in February 2023, Povorcitinib (previously INCB54707) is an oral JAK1 inhibitor that Incyte has reported new 52-week findings from a Phase 2 study examining its effectiveness and safety in treating adult patients with hidradenitis suppurative (HS).

The study previously met its primary endpoint, showing that at Week 16 of the double-blind, placebo-controlled phase, patients receiving povorcitinib once daily (QD) had significantly greater decreases from baseline in Abscess and Inflammatory Nodule (AN) count compared to placebo (least squares mean change, 2.5 [0.9], placebo vs. 5.2 [0.9], P=0.0277, povorcitinib 15 mg; 6.9.

Competitive Landscape

The major global players in the market include: Pfizer Inc., Eli Lilly and Company, AbbVie Inc., UCB S.A., Incyte Corporation, Novartis AG, Boehringer Ingelheim, Aclaris Therapeutics, Inc., InflaRx N.V., and Moonlake Immunotherapeutics among others.

Why Purchase the Report?

To visualize the Global Hidradenitis Suppurativa Market segmentation based on the clinical stage, skin condition, treatment type, route of administration, end-user, distribution channel, and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous hidradenitis suppurativa market-level data points with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The Global Hidradenitis Suppurativa Market Report Would Provide Approximately 85 Tables, 93 Figures And 200+ pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Clinical Stage
3.2. Snippet by Skin Condition
3.3. Snippet by Treatment Type
3.4. Snippet by Route of Administration
3.5. Snippet by Distribution Channel
3.6. Snippet by End-user
3.7. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing Prevalence of hidradenitis suppurativa
- 4.1.2. Restraints
  - 4.1.2.1. High cost associated with the treatment
- 4.1.3. Opportunity
  - 4.1.3.1. Increasing research and development activities
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Clinical Stage

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical Stage
- 9.1.2. Market Attractiveness Index, By Clinical Stage
9.2. Hurley Stage 1*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Hurley Stage 2
9.4. Hurley Stage 3

10. By Skin Condition

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Skin Condition
- 10.1.2. Market Attractiveness Index, By Skin Condition
10.2. Folliculitis*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Pimples
10.4. Boils
10.5. Deep-Acne
10.6. Others

11. By Treatment Type

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 11.1.2. Market Attractiveness Index, By Treatment Type
11.2. Surgery*
- 11.2.1. Introduction
- 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Medications
- 11.3.1. Biologics
- 11.3.2. Antibiotics
- 11.3.3. Hormonal Therapy
- 11.3.4. Immunosuppressive Drugs
- 11.3.5. Zinc Supplements
- 11.3.6. Retinoids
- 11.3.7. Pain Medication
11.4. Photodynamic Therapy (PDT)
11.5. Laser Treatment
11.6. Others

12. By Route of Administration

12.1. Introduction
- 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 12.1.2. Market Attractiveness Index, By Route of Administration
12.2. Oral*
- 12.2.1. Introduction
- 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Parenteral
12.4. Others

13. By End-user

13.1. Introduction
- 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 13.1.2. Market Attractiveness Index, By End-user
13.2. Hospitals*
- 13.2.1. Introduction
- 13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
13.3. Specialty Clinics
13.4. Homecare
13.5. Others

14. By Distribution Channel

14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.1.2. Market Attractiveness Index, By Distribution Channel

14.2. Hospital Pharmacy*
- 14.2.1. Introduction
- 14.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
14.3. Retail Pharmacy
14.4. Online Pharmacy
14.5. Others

15. By Region

15.1. Introduction
- 15.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 15.1.2. Market Attractiveness Index, By Region
15.2. North America
- 15.2.1. Introduction
- 15.2.2. Key Region-Specific Dynamics
- 15.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical stage
- 15.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Skin Condition
- 15.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 15.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 15.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 15.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 15.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 15.2.9.1. The U.S.
  - 15.2.9.2. Canada
  - 15.2.9.3. Mexico
15.3. Europe
- 15.3.1. Introduction
- 15.3.2. Key Region-Specific Dynamics
- 15.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical stage
- 15.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Skin Condition
- 15.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 15.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 15.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 15.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 15.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 15.3.9.1. Germany
  - 15.3.9.2. The U.K.
  - 15.3.9.3. France
  - 15.3.9.4. Italy
  - 15.3.9.5. Spain
  - 15.3.9.6. Rest of Europe
15.4. South America
- 15.4.1. Introduction
- 15.4.2. Key Region-Specific Dynamics
- 15.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical stage
- 15.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Skin Condition
- 15.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 15.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 15.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 15.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 15.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 15.4.9.1. Brazil
  - 15.4.9.2. Argentina
  - 15.4.9.3. Rest of South America
15.5. Asia-Pacific
- 15.5.1. Introduction
- 15.5.2. Key Region-Specific Dynamics
- 15.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical stage
- 15.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Skin Condition
- 15.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 15.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 15.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 15.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 15.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 15.5.9.1. China
  - 15.5.9.2. India
  - 15.5.9.3. Japan
  - 15.5.9.4. Australia
  - 15.5.9.5. Rest of Asia-Pacific
15.6. Middle East and Africa
- 15.6.1. Introduction
- 15.6.2. Key Region-Specific Dynamics
- 15.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical stage
- 15.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Skin Condition
- 15.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 15.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 15.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 15.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

16. Competitive Landscape

16.1. Competitive Scenario
16.2. Product Benchmarking
16.3. Company Share Analysis
16.4. Key Developments and Strategies

17. Company Profiles

17.1. Pfizer Inc.*
- 17.1.1. Company Overview
- 17.1.2. Product Portfolio and Description
- 17.1.3. Financial Overview
- 17.1.4. Key Developments
17.2. Eli Lilly and Company
17.3. AbbVie Inc.
17.4. UCB S.A.
17.5. Incyte Corporation
17.6. Novartis AG
17.7. Boehringer Ingelheim
17.8. Aclaris Therapeutics, Inc.
17.9. InflaRx N.V.
17.10. Moonlake Immunotherapeutics

LIST NOT EXHAUSTIVE

18. Appendix

18.1. About Us and Services
18.2. Contact Us

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격

PDF & Excel (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,350

￦ 6,173,000

PDF & Excel (Multiple User License)

PDF 보고서를 동일 사업장에서 7명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,850

￦ 6,882,000

PDF & Excel (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 7,850

￦ 11,139,000

※ 부가세 별도

세계의 화농성한선염 시장(2023-2030년)

Global Hidradenitis Suppurativa Market - 2023-2030

시장 개요

시장 역학

적극적인 주요 업체들이 예측 기간 동안 세계 화농성한선염 시장의 성장을 촉진

화농성한선염 환자 수의 증가는 예측 기간 동안 화농성한선염 시장의 성장을 촉진

산학협력은 세계 화농성한선염 시장 성장 기회를 제공

COVID-19 영향 분석

러시아-우크라이나 분쟁 분석

목차

제1장 조사 방법과 범위

제2장 정의와 개요

제3장 주요 요약

제4장 시장 역학

제5장 업계 분석

제6장 COVID-19 분석

제7장 러시아와 우크라이나의 전쟁 분석

제8장 인공 지능 분석

제9장 임상 단계별

제10장 피부 상태별

제11장 치료 유형별

제12장 투여 경로별

제13장 최종사용자별

제14장 유통 채널별

제15장 지역별

제16장 경쟁 상황

제17장 기업 개요

제18장 부록